RT Journal Article
SR Electronic
T1 Biologic correlates of beneficial convalescent plasma therapy in a COVID-19 patient reveal disease resolution mechanisms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.03.22269612
DO 10.1101/2022.02.03.22269612
A1 Natalie Bruiners
A1 Valentina Guerrini
A1 Rahul Ukey
A1 Ryan Dikdan
A1 Jason Yang
A1 Pankaj Kumar Mishra
A1 Alberta Onyuka
A1 Deborah Handler
A1 Joshua Vieth
A1 Mary Carayannopulos
A1 Shuang Guo
A1 Maressa Pollen
A1 Abraham Pinter
A1 Sanjay Tyagi
A1 Daniel Feingold
A1 Claire Philipp
A1 Steven Libutti
A1 Maria Laura Gennaro
YR 2022
UL http://medrxiv.org/content/early/2022/02/03/2022.02.03.22269612.abstract
AB Background While the biomarkers of COVID-19 severity have been thoroughly investigated, the key biological dynamics associated with COVID-19 resolution are still insufficiently understood.Main body We report a case of full resolution of severe COVID-19 due to convalescent plasma transfusion in a patient with underlying multiple autoimmune syndrome. Following transfusion, the patient showed fever remission, improved respiratory status, and rapidly decreased viral burden in respiratory fluids and SARS-CoV-2 RNAemia. Longitudinal unbiased proteomic analysis of plasma and single-cell transcriptomics of peripheral blood cells conducted prior to and at multiple times after convalescent plasma transfusion identified the key biological processes associated with the transition from severe disease to disease-free state. These included (i) temporally ordered upward and downward changes in plasma proteins reestablishing homeostasis and (ii) post-transfusion disappearance of a particular subset of dysfunctional monocytes characterized by hyperactivated Interferon responses and decreased TNF-α signaling.Conclusions Monitoring specific subsets of innate immune cells in peripheral blood may provide prognostic keys in severe COVID-19. Moreover, understanding disease resolution at the molecular and cellular level should contribute to identify targets of therapeutic interventions against severe COVID-19.Competing Interest StatementRutgers University has filed for patent protection for various aspects of anti-SARS-CoV-2 antibody detection and its uses. M.L.G. is a consultant for Biomerieux.Funding StatementThis work was funded by NIH grants R01 HL149450, R01 HL149450-S1, R61 HD105619, R01 AI158911, U01 AI122285-S1, UL1 TR003017, and R00 GM118907. Work performed at the Rutgers Biological Mass Spectrometry Facility was partially supported by NIH S10 OD025140.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study activities were approved by the Rutgers Institutional Review Board (Pro2020000655).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors